Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis

Next Previous
X
Search
Trial Profile

A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Helixmith; ViroMed

    • Most Recent Events

    • 09 Feb 2017 According to VM BioPharma media release, clinical safety and tolerability data was published online at the scientific journal, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and will be published in a future print issue of the journal.
    • 17 May 2016 According to a ViroMed media release, the US FDA granted fast track designation to VM202 for the potential treatment of ALS. ViroMed expects the publication of data from this trial in H2 2016.
    • 22 Jan 2016 Status changed from active, no longer recruiting to completed, according to a ViroMed Co. media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top